



■ TEL. : 022 - 6825 2525
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 15.09.2020

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Sub: Submission of Un-Audited Standalone and Consolidated Financial Results for quarter ended 30th June, 2020 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref: Parnax Lab Limited, Script Code- 506128

Dear Sir,

Kindly find enclosed herewith the following:


1. A Copy of Standalone & Consolidated Un-Audited Financial results with Limited Review Report of the Company for the quarter ended 30th June 2020;

Kindly take on record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For PARNAX LAB LIMITED



**NAMRATA KAMBLI
COMPANY SECRETARY & COMPLIANCE OFFICER**

Encl: As above

To

The Board of Directors,

Parnax Lab Limited,

114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022

1. We have reviewed the unaudited standalone financial results of **Parnax Lab Limited** (“the company”) for the quarter and three months ended June 30, 2020 which are included in the accompanying “Statement of Unaudited Standalone Financial Result for the quarter and three months ended June 30, 2020” together with the relevant notes thereon (“the Statement”). The Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 ‘Review on Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than as audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants

(FRN: 120241W)

Vinod Ladha

(Vinod Ladha)

Partner

M. No. : 104151

Place : Mumbai

Dated : 15th September, 2020

UDIN : 20104151 AAAACH2380



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 68252525, Fax : 2405 7708, Email : compliance@naxparlab.com, Website : www.naxparlab.com
CIN-L36912MH1982PLC027925

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2020


(Rs. in Lakhs)

S. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
I	Revenue from Operations	21.74	229.53	146.03	767.95
II	Other Income	0.73	16.03	7.25	41.58
III	Total Revenue (I+II)	22.47	245.56	153.28	809.53
IV	Expenses				
	a) Cost of Material Consumed	0.08	64.26	50.25	260.55
	b) Purchase of Stock in trade	15.57	56.25	34.06	170.55
	c) Changes in inventories of finished goods, Work in progress and stock in trade	-	-	-	-
	d) Employee benefits expenses	10.91	12.26	11.84	51.34
	e) Finance Costs	21.72	20.97	24.79	137.85
	f) Depreciation and amortisation expenses	1.10	1.08	1.09	4.38
	g) Other expenses	10.31	66.73	43.61	232.06
	Total Expenses (IV)	59.69	221.55	165.64	856.73
V	Profit/(loss) before exceptional items and tax (III-IV)	(37.22)	24.01	(12.36)	(47.20)
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	(37.22)	24.01	(12.36)	(47.20)
VIII	Tax expense				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	-	153.25	-	153.25
	c) Short (Excess) Prov for Tax for Earlier Years	-	-	-	-
IX	Profit/ (Loss) for the period (VII-VIII)	(37.22)	(129.24)	(12.36)	(200.45)
X	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	0.45	-	0.45
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.12)	-	(0.12)
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XI	Total Other Comprehensive Income for the period	-	0.33	-	0.33
XII	Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)	(37.22)	(128.91)	(12.36)	(200.12)
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49
XiV	Earning per equity share (Not Annualised)				
	(1) Basic	(0.44)	(1.52)	(0.15)	(2.36)
	(2) Diluted	(0.44)	(1.52)	(0.15)	(2.36)

Notes-

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on September 15, 2020.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2020
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter ended June 30, 2020.
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

By Order of the Board
For Parnax Lab Limited



Prakash M Shah
Director & CEO
DIN NO: 00440980

Place : Mumbai
Date : 15-09-2020

To

**The Board of Directors,
Parnax Lab Limited,**

114, Building No. 8, Jogani Industrial Complex,
Chunabhatti, Mumbai - 400 022

1. We have reviewed the unaudited Consolidated financial results of **Parnax Lab Limited** ("the company") and **Naxpar Pharma Private Limited** ("the Subsidiary") for the quarter and three months ended June 30, 2020 which are included in the accompanying "Statement of Unaudited Consolidated Financial Result for the quarter and three months ended June 30, 2020" together with the relevant notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than as audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants

(FRN: 120241W)

Vinod Ladha

(Vinod Ladha)

Partner

M. No. : 104151

Place : Mumbai

Dated : 15th September, 2020

UDIN : 20104151 AAAACIU393



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 68252525, Fax : 2405 7708, Email : compliance@naxparlab.com, Website : www.naxparlab.com
CIN:-L36912MH1982PLC027925

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2020

S. No.	Particulars	Quarter Ended			(Rs. in Lakhs)
		30.06.2020	31.03.2020	30.06.2019	Year Ended
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from Operations	1,746.16	2,348.90	2,066.35	9,531.48
II	Other Income	2.66	37.64	7.50	66.23
III	Total Revenue (I+II)	1,748.82	2,386.54	2,073.85	9,597.71
IV	Expenses				
	a) Cost of Material Consumed	824.24	1,061.70	899.11	4,529.59
	b) Purchase of Stock in trade	47.64	1.17	7.02	87.97
	c) Changes in inventories of finished goods, Work in progress and stock in trade	(32.06)	68.45	38.85	(90.34)
	d) Employee benefits expenses	269.99	328.93	357.89	1,407.98
	e) Finance Cost	124.96	111.37	101.49	460.18
	f) Depreciation and amortisation expenses	122.80	125.75	105.67	445.94
	g) Other expenses	368.02	846.64	556.50	2,953.12
	Total Expenses (IV)	1,725.59	2,544.01	2,066.53	9,794.44
V	Profit/(loss) before exceptional items and tax (III-IV)	23.23	(157.47)	7.32	(196.73)
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	23.23	(157.47)	7.32	(196.73)
VIII	Tax expense				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	-	98.49	-	98.49
	c) Short (Excess) Prov for Tax for Earlier Years	-	0.79	-	(3.61)
IX	Profit/(Loss) After Tax for the period (VII-VIII)	23.23	(256.75)	7.32	(291.61)
X	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	(2.87)	-	(2.87)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	0.75	-	0.75
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XI	Total Other Comprehensive Income for the period	-	(2.12)	-	(2.12)
XII	Total Comprehensive Income comprising profit and other comprehensive income for the period (IX + XIII)	23.23	(258.87)	7.32	(293.73)
XIII	Total profit/(loss) for the year attributable to:				
	- Owners of the Company	23.11	(256.50)	7.28	(291.43)
	- Non-controlling interests	0.12	(0.25)	0.04	(0.18)
XIV	Other Comprehensive income attributable to:				
	- Owners of the Company	-	(2.12)	-	(2.12)
	- Non-controlling interests	-	(0.01)	-	(0.01)
XV	Total Comprehensive income attributable to:				
	- Owners of the Company	23.11	(258.62)	7.28	(293.54)
	- Non-controlling interests	0.12	(0.26)	0.04	(0.19)
XVI	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49
XVII	Earning per equity share (Not Annualised)				
	(1) Basic	0.27	(3.02)	0.09	(3.43)
	(2) Diluted	0.27	(3.02)	0.09	(3.43)

Notes-

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on September 15, 2020
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2020
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- The Group is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter ended June 30, 2020.
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

By Order of the Board
For Parnax Lab Limited

Prakash M Shah
Whole Time Director & CEO
DIN NO: 00440980

Place : Mumbai
Date : 15-09-2020

